Progress in HIV vaccine development

Denise C. Hsu, Robert J. O'Connell*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

63 Scopus citations


An HIV-1 vaccine is needed to curtail the HIV epidemic. Only one (RV144) out of the 6 HIV-1 vaccine efficacy trials performed showed efficacy. A potential mechanism of protection is the induction of functional antibodies to V1V2 region of HIV envelope. The 2 main current approaches to the generation of protective immunity are through broadly neutralizing antibodies (bnAb) and induction of functional antibodies (non-neutralizing Abs with other potential anti-viral functions). Passive immunization using bnAb has advanced into phase II clinical trials. The induction of bnAb using mimics of the natural Env trimer or B-cell lineage vaccine design is still in pre-clinical phase. An attempt at optimization of protective functional antibodies will be assessed next with the efficacy trial (HVTN702) about to start. With on-going optimization of prime/boost strategies, the development of mosaic immunogens, replication competent vectors, and emergence of new strategies designed to induce bnAb, the prospects for a preventive HIV vaccine have never been more promising.

Original languageEnglish
Pages (from-to)1018-1030
Number of pages13
JournalHuman Vaccines and Immunotherapeutics
Issue number5
StatePublished - 4 May 2017
Externally publishedYes


  • HIV
  • RV144
  • broadly neutralizing antibodies
  • functional antibodies
  • vaccine


Dive into the research topics of 'Progress in HIV vaccine development'. Together they form a unique fingerprint.

Cite this